The current exploratory analysis of the BOLERO-1 trial evaluated the efficacy and safety of everolimus in combination with trastuzumab and paclitaxel in Asian patients with HER2+ advanced breast cancer. This evidence concerns the gene ERBB2 and breast cancer.